Skip to main content
GutCited

Bifidobacterium longum لـ Irritable Bowel Syndrome (IBS)

B

RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dlongum\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

الخلاصة

RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.

Key Study Findings

Meta-Analysis n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None مقابل: placebo Outcome: quality of life, depression, and anxiety in IBS … التأثير: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression) None

المجتمع المدروس: patients with irritable bowel syndrome

Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None مقابل: placebo Outcome: improvement in key IBS symptoms التأثير: None None

المجتمع المدروس: patients with IBS from 32 RCTs evaluating 10 probiotic strains

In Vitro n=35
A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum …
Dose: 1e6 CFU/mL مقابل: IBS supernatants without probiotic Outcome: Caco-2 paracellular permeability التأثير: None <0.001

المجتمع المدروس: IBS patients (28) and asymptomatic controls (7)

Review
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.
Dose: None مقابل: None Outcome: IBS symptom management via NLRP3 inhibition التأثير: None None

المجتمع المدروس: Patients with IBS (narrative review)

Controlled Clinical Trial n=51 12 weeks Open-label
Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and …
Dose: None مقابل: Pre-treatment baseline Outcome: IBS-SSS score reduction التأثير: None None

المجتمع المدروس: IBS-D and IBS-C patients

Observational Study n=37 8 weeks Open-label
An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms …
Dose: None مقابل: None Outcome: Total IBS symptom score (TISS) التأثير: 43.4% TISS reduction; >60% >=30% responders None

المجتمع المدروس: Adults with IBS (Rome IV criteria)

Key Statistics

4

الدراسات

600

المشاركون

Positive

B

التقييم

Referenced Papers

Terapevticheskii arkhiv 2023 3 اقتباسات
The Cochrane database … 2020 14 اقتباسات
Journal of gastroenterology … 2017 32 اقتباسات

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

الجرعات الشائعة

general:
1-10 billion CFU/day
ibssupport:
1 billion CFU/day (35624 strain, marketed as Alflorex/Align)

الحد الأعلى: Well-tolerated up to 10 billion CFU/day in clinical trials

الجرعات المدروسة في الأبحاث

الجرعة المدة التأثير ن
None -- Positive 3154
None -- Positive --
1e6 CFU/mL -- Positive 35
None -- Positive --
None 12 weeks Positive 51
None 8 weeks Positive 37
1x10^10 CFU daily 6 weeks Positive 35
2 g 4 weeks Mixed --

أفضل وقت للتناول: On an empty stomach or before meals

Safety & Side Effects

الآثار الجانبية المُبلّغ عنها

  • Mild gas and bloating during initial use
  • Occasional abdominal discomfort
  • Rare loose stools
  • Very rare: bacteremia in immunocompromised individuals

التفاعلات المعروفة

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (use with caution in immunocompromised patients)

الحد الأقصى المسموح به: Well-tolerated up to 10 billion CFU/day in clinical trials

استشر مقدم الرعاية الصحية دائماً قبل البدء بأي مكمل غذائي.

Frequently Asked Questions

Does Bifidobacterium longum help with Irritable Bowel Syndrome (IBS)?
Based on 4 studies with 600 participants, there is moderate evidence from clinical studies that Bifidobacterium longum may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Bifidobacterium longum should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium longum?
Reported side effects may include Mild gas and bloating during initial use, Occasional abdominal discomfort, Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium longum and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 600 total participants. The overall direction of effect is positive.

Related Evidence

إخلاء مسؤولية FDA: لم تُقيَّم هذه البيانات من قبل إدارة الغذاء والدواء (FDA). لا تهدف المنتجات والمعلومات الواردة في هذا الموقع إلى تشخيص أو علاج أو شفاء أو الوقاية من أي مرض. تستند تقييمات الأدلة المعروضة إلى تحليلنا للأبحاث المحكّمة المنشورة ولا تُشكّل نصيحة طبية. استشر مقدم الرعاية الصحية دائماً قبل البدء بأي نظام مكملات.